MPS Pharmaa（531686）株式概要MPSファーマ・リミテッドは、インド国内外において医薬品の製造、販売、貿易、輸出を行っている。 詳細531686 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6リスク分析意味のある時価総額がありません ( ₹35M )収益が 100 万ドル未満 ( ₹356K )株式の流動性は非常に低い キャッシュランウェイが1年未満である すべてのリスクチェックを見る531686 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹1.8147.5k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-74m41m2016201920222025202620282031Revenue ₹54.9kEarnings ₹8.1kAdvancedSet Fair ValueView all narrativesMPS Pharmaa Limited 競合他社Decipher LabsSymbol: BSE:524752Market cap: ₹62.9mBeryl DrugsSymbol: BSE:524606Market cap: ₹116.1mFabino EnterprisesSymbol: BSE:543444Market cap: ₹42.7mStarsource MultitradeSymbol: BSE:506365Market cap: ₹163.5m価格と性能株価の高値、安値、推移の概要MPS Pharmaa過去の株価現在の株価₹1.8152週高値₹3.0152週安値₹1.57ベータ-0.0331ヶ月の変化4.62%3ヶ月変化9.70%1年変化-34.18%3年間の変化-21.65%5年間の変化70.75%IPOからの変化-84.45%最新ニュースお知らせ • May 18MPS Pharmaa Limited to Report Q4, 2026 Results on May 28, 2026MPS Pharmaa Limited announced that they will report Q4, 2026 results on May 28, 2026お知らせ • Jan 22MPS Pharmaa Limited to Report Q3, 2026 Results on Feb 02, 2026MPS Pharmaa Limited announced that they will report Q3, 2026 results on Feb 02, 2026お知らせ • Nov 04MPS Pharmaa Limited to Report Q2, 2026 Results on Nov 14, 2025MPS Pharmaa Limited announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Sep 03MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, Indiaお知らせ • Aug 02MPS Pharmaa Limited to Report Q1, 2026 Results on Aug 12, 2025MPS Pharmaa Limited announced that they will report Q1, 2026 results on Aug 12, 2025お知らせ • May 19MPS Pharmaa Limited to Report Q4, 2025 Results on May 28, 2025MPS Pharmaa Limited announced that they will report Q4, 2025 results on May 28, 2025最新情報をもっと見るRecent updatesお知らせ • May 18MPS Pharmaa Limited to Report Q4, 2026 Results on May 28, 2026MPS Pharmaa Limited announced that they will report Q4, 2026 results on May 28, 2026お知らせ • Jan 22MPS Pharmaa Limited to Report Q3, 2026 Results on Feb 02, 2026MPS Pharmaa Limited announced that they will report Q3, 2026 results on Feb 02, 2026お知らせ • Nov 04MPS Pharmaa Limited to Report Q2, 2026 Results on Nov 14, 2025MPS Pharmaa Limited announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Sep 03MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, Indiaお知らせ • Aug 02MPS Pharmaa Limited to Report Q1, 2026 Results on Aug 12, 2025MPS Pharmaa Limited announced that they will report Q1, 2026 results on Aug 12, 2025お知らせ • May 19MPS Pharmaa Limited to Report Q4, 2025 Results on May 28, 2025MPS Pharmaa Limited announced that they will report Q4, 2025 results on May 28, 2025お知らせ • Oct 31MPS Pharmaa Limited to Report Q2, 2025 Results on Nov 14, 2024MPS Pharmaa Limited announced that they will report Q2, 2025 results on Nov 14, 2024お知らせ • Sep 03MPS Pharmaa Limited, Annual General Meeting, Sep 28, 2024MPS Pharmaa Limited, Annual General Meeting, Sep 28, 2024, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, Indiaお知らせ • Jul 30MPS Pharmaa Limited to Report Q1, 2025 Results on Aug 13, 2024MPS Pharmaa Limited announced that they will report Q1, 2025 results on Aug 13, 2024お知らせ • May 16MPS Pharmaa Limited to Report Q4, 2024 Results on May 30, 2024MPS Pharmaa Limited announced that they will report Q4, 2024 results on May 30, 2024お知らせ • Oct 31MPS Pharmaa Limited to Report Q2, 2023 Results on Nov 09, 2023MPS Pharmaa Limited announced that they will report Q2, 2023 results on Nov 09, 2023お知らせ • Aug 30MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2023MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2023, at 09:30 Indian Standard Time.お知らせ • Aug 03MPS Pharmaa Limited to Report Q1, 2024 Results on Aug 12, 2023MPS Pharmaa Limited announced that they will report Q1, 2024 results at 3:30 PM, Indian Standard Time on Aug 12, 2023お知らせ • Jul 06MPS Pharmaa Limited Announces Resignation of Manoj Kumar Jain from the Position of the Independent Director of the Company with Immediate EffectMPS Pharmaa Limited announced that the company has received on 05th July, 2023, a resignation letter dated 04th July, 2023 from Mr. Manoj Kumar Jain, Independent Director of the Company wherein he has tendered his resignation from the position of the Independent Director of the Company with immediate effect. Resignation due to personal reasons commitments and business commitments. Mr. Manoj Kumar Jain has been associated with the company since 26-12-2013.Board Change • Jun 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 17MPS Pharmaa Limited to Report Q4, 2023 Results on May 29, 2023MPS Pharmaa Limited announced that they will report Q4, 2023 results on May 29, 2023Board Change • Mar 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 24MPS Pharmaa Limited to Report Q3, 2023 Results on Feb 03, 2023MPS Pharmaa Limited announced that they will report Q3, 2023 results on Feb 03, 2023Board Change • Jan 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 03Advik Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022Advik Laboratories Limited announced that they will report Q2, 2023 results on Nov 12, 2022Board Change • Oct 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 02Advik Laboratories Limited, Annual General Meeting, Sep 29, 2022Advik Laboratories Limited, Annual General Meeting, Sep 29, 2022, at 09:30 Indian Standard Time. Location: 138, Roz- Ka - Meo Industrial Area, Sohna, Distt. Mewat-122 103, Haryana Sohna IndiaBoard Change • Sep 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 16First quarter 2023 earnings released: ₹0.11 loss per share (vs ₹0.15 loss in 1Q 2022)First quarter 2023 results: ₹0.11 loss per share (up from ₹0.15 loss in 1Q 2022). Net loss: ₹2.03m (loss narrowed 27% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.お知らせ • Jul 31Advik Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022Advik Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022お知らせ • Apr 16Advik Laboratories Limited announced that it expects to receive INR 62.5 million in funding from Neelabh Spinning Mills Pvt. Ltd., Omkam Securities Private Limited, Dhiru Builders and Promoters Private Limited and other investorsAdvik Laboratories Limited announced a private placement of up to 25,000,000 pre-paid warrants at a price of INR 2.5 per warrant for gross proceeds of up to INR 62,500,000 on April 15, 2022. The transaction will include participation from promoters Aditya Aggarwal, Seema Aggarwal, and Omkam Securities Private Limited, and non-promoters Neelabh Spinning Mills Pvt. Ltd., and returning investor Dhiru Builders and Promoters Private Limited. The total issue price of warrants is INR 10, of which the company will receive 25% as upfront payment at the time of allotment of warrants and the remaining 75% will be paid upon exercise of warrants. Each warrant is exercisable to acquire 1 common share of the company, at an exercise price of INR 7.5 per share for a period of 18 months from the date of closing. The company will issue securities on preferential basis. The transaction has been approved by the board of directors of the company, and is subject to approval from company's shareholders at its extraordinary general meeting scheduled to be held on May 18, 2022, and approval from applicable regulatory authorities.Reported Earnings • Jul 06Full year 2021 earnings released: ₹2.31 loss per share (vs ₹0.61 loss in FY 2020)Full year 2021 results: Net loss: ₹44.2m (loss widened 279% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings.株主還元531686IN PharmaceuticalsIN 市場7D0%0.5%3.8%1Y-34.2%8.1%0.5%株主還元を見る業界別リターン: 531686過去 1 年間で8.1 % の収益を上げたIndian Pharmaceuticals業界を下回りました。リターン対市場: 531686は、過去 1 年間で0.5 % のリターンを上げたIndian市場を下回りました。価格変動Is 531686's price volatile compared to industry and market?531686 volatility531686 Average Weekly Movementn/aPharmaceuticals Industry Average Movement7.2%Market Average Movement7.1%10% most volatile stocks in IN Market10.2%10% least volatile stocks in IN Market4.7%安定した株価: 531686の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の531686のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト199418Peeyush Aggarwalwww.mpspharmaa.comMPS Pharmaa Limited は、インド国内外において医薬品の製造、販売、貿易、輸出を行っている。抗菌薬、抗アレルギー薬、抗真菌薬、駆虫薬、抗高血圧薬、抗マラリア薬、抗結核薬、副腎皮質ステロイド薬、勃起不全薬、胃腸薬、鎮静薬などのジェネリック医薬品や、鎮痛薬、解熱薬、抗炎症薬などを提供している。また、医療用製品も提供している。また、東アジア、東南アジア、中東、南米、アフリカに製品を輸出している。同社は以前はAdvik Laboratories Limitedとして知られていたが、2022年12月にMPS Pharmaa Limitedに社名を変更した。MPS Pharmaa Limitedは1994年に設立され、インドのニューデリーに拠点を置く。もっと見るMPS Pharmaa Limited 基礎のまとめMPS Pharmaa の収益と売上を時価総額と比較するとどうか。531686 基礎統計学時価総額₹34.59m収益（TTM）-₹10.20m売上高(TTM)₹356.00k97.2xP/Sレシオ-3.4xPER（株価収益率531686 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計531686 損益計算書（TTM）収益₹356.00k売上原価₹0売上総利益₹356.00kその他の費用₹10.56m収益-₹10.20m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.53グロス・マージン100.00%純利益率-2,865.17%有利子負債／自己資本比率10,983.9%531686 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 22:29終値2026/06/15 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MPS Pharmaa Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 18MPS Pharmaa Limited to Report Q4, 2026 Results on May 28, 2026MPS Pharmaa Limited announced that they will report Q4, 2026 results on May 28, 2026
お知らせ • Jan 22MPS Pharmaa Limited to Report Q3, 2026 Results on Feb 02, 2026MPS Pharmaa Limited announced that they will report Q3, 2026 results on Feb 02, 2026
お知らせ • Nov 04MPS Pharmaa Limited to Report Q2, 2026 Results on Nov 14, 2025MPS Pharmaa Limited announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Sep 03MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, India
お知らせ • Aug 02MPS Pharmaa Limited to Report Q1, 2026 Results on Aug 12, 2025MPS Pharmaa Limited announced that they will report Q1, 2026 results on Aug 12, 2025
お知らせ • May 19MPS Pharmaa Limited to Report Q4, 2025 Results on May 28, 2025MPS Pharmaa Limited announced that they will report Q4, 2025 results on May 28, 2025
お知らせ • May 18MPS Pharmaa Limited to Report Q4, 2026 Results on May 28, 2026MPS Pharmaa Limited announced that they will report Q4, 2026 results on May 28, 2026
お知らせ • Jan 22MPS Pharmaa Limited to Report Q3, 2026 Results on Feb 02, 2026MPS Pharmaa Limited announced that they will report Q3, 2026 results on Feb 02, 2026
お知らせ • Nov 04MPS Pharmaa Limited to Report Q2, 2026 Results on Nov 14, 2025MPS Pharmaa Limited announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Sep 03MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2025, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, India
お知らせ • Aug 02MPS Pharmaa Limited to Report Q1, 2026 Results on Aug 12, 2025MPS Pharmaa Limited announced that they will report Q1, 2026 results on Aug 12, 2025
お知らせ • May 19MPS Pharmaa Limited to Report Q4, 2025 Results on May 28, 2025MPS Pharmaa Limited announced that they will report Q4, 2025 results on May 28, 2025
お知らせ • Oct 31MPS Pharmaa Limited to Report Q2, 2025 Results on Nov 14, 2024MPS Pharmaa Limited announced that they will report Q2, 2025 results on Nov 14, 2024
お知らせ • Sep 03MPS Pharmaa Limited, Annual General Meeting, Sep 28, 2024MPS Pharmaa Limited, Annual General Meeting, Sep 28, 2024, at 09:30 Indian Standard Time. Location: 138, roz-ka-meo industrial area, sohna, distt, mewat- 122103, haryana, India
お知らせ • Jul 30MPS Pharmaa Limited to Report Q1, 2025 Results on Aug 13, 2024MPS Pharmaa Limited announced that they will report Q1, 2025 results on Aug 13, 2024
お知らせ • May 16MPS Pharmaa Limited to Report Q4, 2024 Results on May 30, 2024MPS Pharmaa Limited announced that they will report Q4, 2024 results on May 30, 2024
お知らせ • Oct 31MPS Pharmaa Limited to Report Q2, 2023 Results on Nov 09, 2023MPS Pharmaa Limited announced that they will report Q2, 2023 results on Nov 09, 2023
お知らせ • Aug 30MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2023MPS Pharmaa Limited, Annual General Meeting, Sep 29, 2023, at 09:30 Indian Standard Time.
お知らせ • Aug 03MPS Pharmaa Limited to Report Q1, 2024 Results on Aug 12, 2023MPS Pharmaa Limited announced that they will report Q1, 2024 results at 3:30 PM, Indian Standard Time on Aug 12, 2023
お知らせ • Jul 06MPS Pharmaa Limited Announces Resignation of Manoj Kumar Jain from the Position of the Independent Director of the Company with Immediate EffectMPS Pharmaa Limited announced that the company has received on 05th July, 2023, a resignation letter dated 04th July, 2023 from Mr. Manoj Kumar Jain, Independent Director of the Company wherein he has tendered his resignation from the position of the Independent Director of the Company with immediate effect. Resignation due to personal reasons commitments and business commitments. Mr. Manoj Kumar Jain has been associated with the company since 26-12-2013.
Board Change • Jun 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 17MPS Pharmaa Limited to Report Q4, 2023 Results on May 29, 2023MPS Pharmaa Limited announced that they will report Q4, 2023 results on May 29, 2023
Board Change • Mar 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 24MPS Pharmaa Limited to Report Q3, 2023 Results on Feb 03, 2023MPS Pharmaa Limited announced that they will report Q3, 2023 results on Feb 03, 2023
Board Change • Jan 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 03Advik Laboratories Limited to Report Q2, 2023 Results on Nov 12, 2022Advik Laboratories Limited announced that they will report Q2, 2023 results on Nov 12, 2022
Board Change • Oct 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 10Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 19Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 02Advik Laboratories Limited, Annual General Meeting, Sep 29, 2022Advik Laboratories Limited, Annual General Meeting, Sep 29, 2022, at 09:30 Indian Standard Time. Location: 138, Roz- Ka - Meo Industrial Area, Sohna, Distt. Mewat-122 103, Haryana Sohna India
Board Change • Sep 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non Independent Director Ram Sharma was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 16First quarter 2023 earnings released: ₹0.11 loss per share (vs ₹0.15 loss in 1Q 2022)First quarter 2023 results: ₹0.11 loss per share (up from ₹0.15 loss in 1Q 2022). Net loss: ₹2.03m (loss narrowed 27% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
お知らせ • Jul 31Advik Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022Advik Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022
お知らせ • Apr 16Advik Laboratories Limited announced that it expects to receive INR 62.5 million in funding from Neelabh Spinning Mills Pvt. Ltd., Omkam Securities Private Limited, Dhiru Builders and Promoters Private Limited and other investorsAdvik Laboratories Limited announced a private placement of up to 25,000,000 pre-paid warrants at a price of INR 2.5 per warrant for gross proceeds of up to INR 62,500,000 on April 15, 2022. The transaction will include participation from promoters Aditya Aggarwal, Seema Aggarwal, and Omkam Securities Private Limited, and non-promoters Neelabh Spinning Mills Pvt. Ltd., and returning investor Dhiru Builders and Promoters Private Limited. The total issue price of warrants is INR 10, of which the company will receive 25% as upfront payment at the time of allotment of warrants and the remaining 75% will be paid upon exercise of warrants. Each warrant is exercisable to acquire 1 common share of the company, at an exercise price of INR 7.5 per share for a period of 18 months from the date of closing. The company will issue securities on preferential basis. The transaction has been approved by the board of directors of the company, and is subject to approval from company's shareholders at its extraordinary general meeting scheduled to be held on May 18, 2022, and approval from applicable regulatory authorities.
Reported Earnings • Jul 06Full year 2021 earnings released: ₹2.31 loss per share (vs ₹0.61 loss in FY 2020)Full year 2021 results: Net loss: ₹44.2m (loss widened 279% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings.
